U.S. Packaging Stock News

If you are looking at AppLovin and wondering whether the current share price lines up with the underlying value, you are not alone. The stock last closed at US$421.63, with a 2.3% gain over 7 days, a 22.4% decline over 30 days, a 31.8% decline year to date, and a 31.6% return over 1 year, plus a very large 3 year return. Recent coverage has focused on AppLovin's position in mobile app marketing and software, including its role in helping app developers manage advertising and user growth,...

If you are wondering whether Vita Coco Company stock is still attractively priced after a strong run, this article will walk through what the current market price might be implying about its value. The share price recently closed at US$55.07, with returns of 10.0% over 7 days, 0.4% over 30 days, 3.0% year to date and 63.4% over 1 year, while the 3 year return stands at 221.9%. Recent attention on Vita Coco has focused on its position in the branded coconut water and functional beverage...

If you are wondering whether Hilton Worldwide Holdings’ current share price still makes sense after a strong run in recent years, a closer look at what you are paying for each dollar of future cash flow can be revealing. The stock last closed at US$313.35, with returns of 5.5% over the past 30 days, 7.0% year to date, 20.7% over 1 year, 117.1% over 3 years and 157.7% over 5 years, which may have shifted how the market views its risk and reward trade off. Recent headlines around Hilton...

In February 2026, Alliant Energy reaffirmed its 2026 consolidated ongoing EPS guidance of US$3.36–US$3.46 and reported 2025 full-year revenue of US$4,362 million with net income of US$810 million, up from US$3,981 million and US$690 million respectively in 2024. The company also highlighted ongoing construction on multiple contracted projects and active negotiations for additional load, underscoring how new customer demand is shaping its earnings outlook. Against this backdrop, we’ll now...

Chevron (CVX) closed out FY 2025 with fourth quarter revenue of US$45.1b and basic EPS of US$1.39, alongside trailing 12 month revenue of US$184.7b and EPS of US$6.65. Over recent quarters, revenue moved between US$44.5b and US$49.2b while quarterly EPS ranged from US$1.39 to US$2.49, giving investors a clear view of how the top line and per share earnings have tracked through the year. With net income of US$2.8b in the latest quarter and trailing 12 month profit of US$12.3b, the focus now...

WeRide stock moves after recent trading performance WeRide (WRD) has drawn attention after a 1-month return of a 16% decline and a 3-month return of a 10% decline, alongside a 1-year total return of a 69% decline from its US$7.27 close. See our latest analysis for WeRide. For WeRide, the weak 1-month and year to date share price returns suggest momentum has been fading, while the 1-year total shareholder return points to prolonged pressure as investors reassess growth potential and risk...

If you are wondering whether Advance Auto Parts shares are now a bargain or still a value trap, this article walks through what the current price is really telling you. The stock recently closed at US$50.44, after a 9.8% decline over the last 7 days, a 6.1% gain over 30 days, a 29.7% gain year to date, a 36.9% gain over 1 year, but with 3 year and 5 year returns of 61.1% and 65.8% declines respectively. These moves sit against a backdrop of ongoing attention on the company’s turnaround...

If you are wondering whether Southern Copper's share price still offers value or if the easy gains are already behind it, you are in the right place. This article focuses on what the current price could mean for long term investors. The stock last closed at US$215.20, with returns of 11.7% over 7 days, 15.2% over 30 days, 46.0% year to date and 146.1% over the past year. This naturally raises questions about growth potential and how risk is now being priced in. Recent headlines around...

Krystal Biotech (KRYS) is back in focus after reporting fourth quarter and full year 2025 earnings, with net income and earnings per share above the prior year and analyst expectations. This has shifted attention squarely to its profit profile. See our latest analysis for Krystal Biotech. That earnings beat has come after a powerful run, with the latest share price at $272.50, a 24.6% 90 day share price return and a 54.5% total shareholder return over the past year. This suggests momentum has...

Popular (BPOP) has drawn fresh attention after recent share price moves, with the stock showing a 15% gain over the past month and 23% over the past 3 months. This has prompted closer scrutiny of its banking fundamentals. See our latest analysis for Popular. Looking beyond the recent 15.0% 1 month share price return, Popular’s 1 year total shareholder return of 44.7% and 5 year total shareholder return of 137.2% show a strong payoff for longer term holders, even as the latest 7 day share...

Hovnanian Enterprises (HOV) opened its 2026 financial year with Q1 revenue of US$632 million and basic EPS of US$2.80, setting a measured tone after a volatile run of quarterly results. The company has seen quarterly revenue move from US$674 million and EPS of US$3.88 in Q1 2025 through periods of both profit and loss, including revenue of US$818 million with a loss per share of US$0.60 in Q4 2025. This puts today’s figures in the middle of a choppy trend that keeps the spotlight firmly on...

Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net...

CareDx (CDNA) just wrapped up FY 2025 with Q4 revenue of US$108.4 million, basic EPS of US$0.08 loss, and net income loss of US$4.1 million, while trailing twelve month figures show revenue of US$379.8 million and a net income loss of US$21.4 million. Over recent quarters, the company has seen revenue move from US$86.6 million in Q2 2025 to US$100.1 million in Q3 2025 and then to US$108.4 million in Q4 2025, with EPS shifting from a US$0.19 loss in Q1 2025 to a small profit of US$0.03 in Q3...

Primoris Services (PRIM) has wrapped up FY 2025 with Q4 revenue of US$1.9b and basic EPS of US$0.96, while trailing twelve month revenue reached about US$7.6b and EPS came in at US$5.09 as earnings grew 52% over the past year. The company has seen revenue move from US$6.4b to US$7.6b and trailing net income rise from US$180.9m to US$274.9m over the last year, presenting a picture of expanding profits and firmer margins across the construction and infrastructure work it delivers. See our full...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...

Setting the scene on ACV Auctions ACV Auctions (ACVA) has drawn investor attention after a prolonged share price slump, with the stock showing negative returns over the past month, past 3 months, and year to date. At a last close of US$4.51, the wholesale digital auction platform sits against a backdrop of reported annual revenue of US$759.6 million and a net loss of US$66.1 million. This raises questions about how the business fundamentals compare with recent market sentiment. See our latest...

Universal Insurance Holdings FY 2025 Earnings Snapshot Universal Insurance Holdings (UVE) has wrapped up FY 2025 with fourth quarter total revenue of US$407.9 million and basic EPS of US$2.40, alongside net income of US$66.6 million as investors weigh these results against a year where net profit margin moved from 3.9% to 11.4% and earnings growth was very large at about 210.5% year over year. Over recent periods the company has seen total revenue shift from US$384.8 million and basic EPS of...

Ternium S.A. has reported its fourth-quarter and full-year 2025 results, with annual sales of US$15,609.09 million and net income of US$425.23 million, and its board intends to propose a total 2025 annual dividend of US$0.27 per share (US$2.70 per ADS), including the interim amount already paid. If shareholders approve the board’s plan at the May 12, 2026 meeting, investors would receive a further US$0.18 per share (US$1.80 per ADS) on May 15, 2026, highlighting how Ternium is balancing a...

Laureate Education (NasdaqGS:LAUR) expanded its share repurchase authorization by $250 million, bringing the total program size to $400 million. The company has already completed a major tranche of this enlarged buyback, reducing its outstanding equity float. The move reflects management’s view of Laureate Education’s business outlook and capital allocation approach. For investors tracking Laureate Education, the larger buyback comes with the stock trading around $33.86, after a 71.9%...

STAAR Surgical (STAA) is back in focus after the U.S. FDA approved an expanded age indication for its EVO and EVO+ Visian Implantable Collamer Lenses, lifting the upper limit from 45 to 60 years. See our latest analysis for STAAR Surgical. The FDA age expansion comes as STAAR Surgical’s 7 day share price return of 12.58% contrasts with a 90 day share price decline of 24.15% and a 3 year total shareholder return decline of 65.58%, suggesting recent momentum after a tough longer stretch. If...

CeriBell (CBLL) has just closed out FY 2025 with Q4 revenue of US$24.8 million and a basic EPS loss of US$0.36, while trailing 12 month revenue reached US$89.1 million and basic EPS over that period sat at a loss of US$1.46. The company has seen quarterly revenue move from US$18.5 million in Q4 2024 to US$24.8 million in Q4 2025, with basic EPS losses over those quarters ranging between US$0.36 and US$0.40, and trailing 12 month net income remaining in loss territory at US$53.4 million for...

Ironwood Pharmaceuticals (IRWD) just closed out FY 2025 with a mixed Q4 print, reporting revenue of US$47.7 million and a small net loss of US$2.3 million, which translated into EPS of US$0.15 for the trailing twelve months. The company has seen revenue move from US$351.4 million on a trailing basis in Q4 2024 to US$296.2 million in Q4 2025, while trailing EPS shifted from roughly flat at US$0.01 to US$0.15. This sets up a picture in which margins have recently firmed even as top line...

Earlier this week, Allegro MicroSystems held an Analyst Day where it outlined a 3–5 year financial model targeting mid-teens revenue growth and gross margins above 55%, prompting research firms to reaffirm positive views on the company’s long-term prospects. This upbeat outlook comes despite Allegro’s recent annual sales and earnings declines and relatively low free cash flow margins, highlighting a tension between ambitious growth targets and current financial constraints. We’ll now explore...